TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19

TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in Chinese city of Wuhan has caused around 906,092 deaths and 28,040,853 confirmed cases worldwide (https://covid19.who.int/, 11 September 2020). In a life-threatening situation, where there is no specific and licensed...

Full description

Bibliographic Details
Main Authors: Mohammad Azam Ansari, Qazi Mohammad Sajid Jamal, Suriya Rehman, Ahmad Almatroudi, Mohammad A. Alzohairy, Mohammad N. Alomary, Takshashila Tripathi, Ali H. Alharbi, Syed Farooq Adil, Mujeeb Khan, M. Shaheer Malik
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:Arabian Journal of Chemistry
Subjects:
SARS-CoV-2
TAT-peptide
3CLpro main protease
COVID-19
In silico
Molecular docking
Online Access:http://www.sciencedirect.com/science/article/pii/S1878535220303713

Internet

http://www.sciencedirect.com/science/article/pii/S1878535220303713

Similar Items